Initial response good. I find it a little weird that a biotech...

Initial response good. I find it a little weird that a biotech at this point and the results can be bought at sub 70c but that's part a reflection on biotech and particularly biotech in pre-commercialisation. Wouldn't sell at these prices and I'm a tad perplexed at those selling on the news. The final dosing for the phase 3 still had to be finalised with the FDA as did DMOAD so there seem plenty of time to get the dosage right. Hopefully the MPS data is significant and could lead to a buy in. End of quarter cash burn will be important and perhaps that's why the market is cautious. Application to TGA significant and I hope they havn't wasted too much on the initial phase 3 with an ineffective dose. GLTA